Peanut Allergy Therapeutics - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the clinical trials landscape of the gene therapy for peanut allergy therapeutics including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, by territory, therapeutic modality, mechanism of action, and target.

Overview of the gene therapy pipeline for peanut allergy therapeutics  

The most prevalent food allergy, peanut allergy, is found extensively in children and adults. The immune system of the body reacts abnormally to one or more than one peanut proteins, resulting in an allergy. This allergy is one of the leading causes of anaphylaxis and may also be consequent in death. Individuals suffering from this allergy exhibit symptoms such as itchy skin, an itching sensation around the mouth or throat, nausea, runny or congested nose, or anaphylaxis. Technavio’s market research analysts report that in 2016, CDC calculated that 6.2% of children under 18 years suffered from food allergies in the US.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the pre-clinical drug development stage. Our market research analysts have also identified that amount of drug molecules under the phase I followed by molecules in the discovery drug development stage. The pipeline landscape in the pipeline analysis report also mentions the same percentage of drug development molecules that are in the phase II and phase III stage, followed by phase I/II drug development stages.  

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of gene therapy molecules for the treatment of peanut allergy therapeutics. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the gene therapy molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are:

•  Allergy therapeutics
• Cambridge Allergy
• DBV Technologies

Therapeutic assessment of the gene therapy pipeline for peanut allergy therapeutics by route of administration

• Oral
• Intravenous
• Sublingual
• Intradermal
• Intradermal + intramuscular
• Transdermal
• Subcutaneous

The oral route of administration (ROA) involves the administration of drug substances through mouth cavity. It has been observed that around four molecule therapeutics for peanut allergy are being developed for oral administration.

Therapeutic assessment of the gene therapy pipeline for peanut allergy therapeutics by therapeutic modality

• Vaccine
• Monoclonal antibody
• Biologicals
• Recombinant fusion protein
• Gene
• Peptide
• Small molecule

According to this pipeline analysis report, majority of the molecules that are currently in the drug development pipeline for peanut allergy therapeutics are being developed as vaccines. These vaccine molecules are a biological preparation that provide active acquired immunity to a disease.  

Technavio also offers customization on reports based on specific client requirement.